Format

Send to

Choose Destination
See comment in PubMed Commons below
Cardiovasc Drugs Ther. 2007 Dec;21(6):445-8.

L-carnitine as an adjunct therapy to percutaneous coronary intervention for non-ST elevation myocardial infarction.

Author information

1
Department of Cardiology, Liaocheng People's Hospital, Liaocheng, Shandong Province, People's Republic of China.

Abstract

OBJECTIVES:

To evaluate the effects of L: -carnitine as an adjunct therapy to percutanenous coronary intervention (PCI) for non-ST elevation acute coronary syndrome (NSTEMI).

MATERIALS AND METHODS:

Ninety-six consecutive patients with NSTEMI were randomized into treatment group (L: -carnitine 5 g IV bolus followed by 10 g/day IV infusion for 3 days), and control group. All patients also underwent PCI within 24 h from the onset of chest pain. The peak values of creatine kinase-MB and troponin-I before and after PCI were observed.

RESULTS:

In the treatment group, the peak values of creatine kinase-MB were significantly lower than the control group at 12 h and 24 h after PCI (P < 0.01). The peak values of troponin-I in the treatment group were also lower than the control group at 8 h after PCI (P < 0.01). Multivariate regression analysis showed that L: -carnitine therapy was an independent predictor for the reduction of creatine kinase-MB (r = 0.596, P < 0.001) or troponin-I (r = 0.633, P < 0.001).

CONCLUSION:

L: -carnitine adjunct therapy appears to be associated with a reduced level of cardiac markers in patients with NSTEMI. These results support a larger clinical trial to investigate the effect of L: -carnitine on cardiac events following PCI.

PMID:
17955358
DOI:
10.1007/s10557-007-6056-9
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center